These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

544 related articles for article (PubMed ID: 32489335)

  • 1. Recent advances in mass spectrometry based clinical proteomics: applications to cancer research.
    Macklin A; Khan S; Kislinger T
    Clin Proteomics; 2020; 17():17. PubMed ID: 32489335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frontiers in mass spectrometry-based clinical proteomics for cancer diagnosis and treatment.
    Haga Y; Minegishi Y; Ueda K
    Cancer Sci; 2023 May; 114(5):1783-1791. PubMed ID: 36661476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Advances in high-throughput proteomic analysis].
    Wu Q; Sui X; Tian R
    Se Pu; 2021 Feb; 39(2):112-117. PubMed ID: 34227342
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mass spectrometry for translational proteomics: progress and clinical implications.
    Baker ES; Liu T; Petyuk VA; Burnum-Johnson KE; Ibrahim YM; Anderson GA; Smith RD
    Genome Med; 2012; 4(8):63. PubMed ID: 22943415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proteogenomic studies on cancer drug resistance: towards biomarker discovery and target identification.
    Fu S; Liu X; Luo M; Xie K; Nice EC; Zhang H; Huang C
    Expert Rev Proteomics; 2017 Apr; 14(4):351-362. PubMed ID: 28276747
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent developments in mass-spectrometry-based targeted proteomics of clinical cancer biomarkers.
    Wenk D; Zuo C; Kislinger T; Sepiashvili L
    Clin Proteomics; 2024 Jan; 21(1):6. PubMed ID: 38287260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Application of targeted mass spectrometry in bottom-up proteomics for systems biology research.
    Manes NP; Nita-Lazar A
    J Proteomics; 2018 Oct; 189():75-90. PubMed ID: 29452276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging Affinity-Based Proteomic Technologies for Large-Scale Plasma Profiling in Cardiovascular Disease.
    Smith JG; Gerszten RE
    Circulation; 2017 Apr; 135(17):1651-1664. PubMed ID: 28438806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advancing translational research and precision medicine with targeted proteomics.
    Uzozie AC; Aebersold R
    J Proteomics; 2018 Oct; 189():1-10. PubMed ID: 29476807
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent advances in clinical proteomics using mass spectrometry.
    Dowling P; Meleady P; Henry M; Clynes M
    Bioanalysis; 2010 Sep; 2(9):1609-15. PubMed ID: 21083289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer proteogenomics: current impact and future prospects.
    Mani DR; Krug K; Zhang B; Satpathy S; Clauser KR; Ding L; Ellis M; Gillette MA; Carr SA
    Nat Rev Cancer; 2022 May; 22(5):298-313. PubMed ID: 35236940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proteomics in colorectal cancer translational research: biomarker discovery for clinical applications.
    de Wit M; Fijneman RJ; Verheul HM; Meijer GA; Jimenez CR
    Clin Biochem; 2013 Apr; 46(6):466-79. PubMed ID: 23159294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of potential protein biomarkers of lung adenocarcinoma in bronchoalveolar lavage fluid by SWATH MS data-independent acquisition and targeted data extraction.
    Ortea I; Rodríguez-Ariza A; Chicano-Gálvez E; Arenas Vacas MS; Jurado Gámez B
    J Proteomics; 2016 Apr; 138():106-14. PubMed ID: 26917472
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An overview of technologies for MS-based proteomics-centric multi-omics.
    Rajczewski AT; Jagtap PD; Griffin TJ
    Expert Rev Proteomics; 2022 Mar; 19(3):165-181. PubMed ID: 35466851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrated proteo-genomic approach for early diagnosis and prognosis of cancer.
    Shukla HD; Mahmood J; Vujaskovic Z
    Cancer Lett; 2015 Dec; 369(1):28-36. PubMed ID: 26276717
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Recent advances in glycopeptide enrichment and mass spectrometry data interpretation approaches for glycoproteomics analyses].
    Liu L; Qin H; Ye M
    Se Pu; 2021 Oct; 39(10):1045-1054. PubMed ID: 34505426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mass spectrometry-based characterization of histones in clinical samples: applications, progress, and challenges.
    Noberini R; Robusti G; Bonaldi T
    FEBS J; 2022 Mar; 289(5):1191-1213. PubMed ID: 33415821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detecting post-translational modification signatures as potential biomarkers in clinical mass spectrometry.
    Mnatsakanyan R; Shema G; Basik M; Batist G; Borchers CH; Sickmann A; Zahedi RP
    Expert Rev Proteomics; 2018 Jun; 15(6):515-535. PubMed ID: 29893147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Harnessing the power of proteomics for identification of oncogenic, druggable signalling pathways in cancer.
    Murray HC; Dun MD; Verrills NM
    Expert Opin Drug Discov; 2017 May; 12(5):431-447. PubMed ID: 28286965
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 28.